MedTrace Logo

Vigabatrin for Cocaine and Alcohol Dependence

NCT01335867 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2019-09-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effectiveness of vigabatrin at reducing drug and alcohol use in individuals addicted to cocaine and alcohol. Vigabatrin is approved for the treatment of seizures. It has not been proven to be effective for the treatment of alcohol or cocaine dependence.

Conditions

  • Alcoholism
  • Cocaine Dependence

Interventions

DRUG

Vigabatrin

Vigabatrin escalated to 3 grams daily for 8 weeks

DRUG

Placebo

Placebo pills

Sponsors & Collaborators

Principal Investigators

  • Kyle M Kampman, M.D. · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2013-04-30
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01335867 on ClinicalTrials.gov